Sunday, October 1, 2023
Clinical Advances in
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), relatively unknown conditions just 2 decades ago, are now the most common causes of chronic liver disease worldwide, affecting an estimated 25% of the world's population. The collective epidemic of NAFLD and NASH closely parallels the epidemics of obesity and type 2 diabetes mellitus. As the prevalence of these conditions continues to increase, predictions are that the prevalence of NAFLD and NASH will also increase, creating unprecedented personal, clinical, and economic burdens. Early disease can be managed with modification of risk factors, and with off-label insulin sensitizers and/or antioxidants in some individuals. And while there are no approved drug regimens to treat NASH, the clinical trial pipeline is very active, with several agents in phase 3 trials. This curriculum will emphasize the importance of risk factor detection and early detection, diagnosis, and treatment -- through either regression or preventing progression of disease -- as means to halting the silent but deadly epidemic.
Supported by an independent educational grant from
Intercept Pharmaceuticals, Inc.
More than 60 agents are in clinical trials for the treatment of NASH, but only 4 have made it to phase 3.
Download
Steering Committee Chair
Chairman
Department of Medicine
Inova Fairfax Medical Campus
Betty and Guy Beatty Center for Integrated Research, Inova Health System
Falls Church, Virginia, United States
Professor of Experimental Hepatology and Honorary Consultant
Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle upon Tyne, United Kingdom
Professor
Division of Gastroenterology and Hepatology
Department of Medical Sciences
University of Turin
Turin, Italy
Director
Liver Institute Northwest
Clinical Professor
Elson S. Floyd College of Medicine
Washington State University
Spokane, Washington, United States
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
Professor
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Hong Kong
Steering Committee Chair
Has disclosed no relevant financial relationships
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Abbott Laboratories; Acuitas Therapeutics; Allergan, Inc.; Blade Therapeutics; BBN Cardio; Cirius Therapeutics; CymaBay Therapeutics; EcoR1 Capital; E3Bio; Eli Lilly and Company; Galmed Pharmaceuticals Ltd.; GENFIT SA; Gilead Sciences, Inc.; Grünenthal Group; HistoIndex Pte Ltd.; Indalo Therapeutics, Inc.; Intercept Pharmaceuticals, Inc.; Inventiva; IQVIA; Janssen Pharmaceuticals; Madrigal Pharmaceuticals, Inc.; MedImmune Inc.; Metacrine; NewGene; NGM Biopharmaceuticals; NorthSea Therapeutics B.V.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc.; Poxel SA; ProSciento; Raptor Pharmaceuticals; SERVIER; Tobira Therapeutics; Viking Therapeutics
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Allergan, Inc.; Bristol-Myers Squibb Company; Dr. Falk Pharma GmbH; GENFIT SA; Gilead Sciences, Inc.
Received grants for clinical research from: AbbVie Inc.; Allergan, Inc.; Antaros Medical AB; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Ellegaard Gottingen Minipigs AS; Eli Lilly and Company; Exalenz Bioscience Ltd.; GENFIT SA; GlaxoSmithKline; Glympse Bio; HistoIndex Pte Ltd.; Intercept Pharmaceuticals, Inc.; iXscient Limited; Nordic Bioscience; Novartis Pharmaceuticals Corporation; Novo Nordisk; One Way Liver, S.L.; Perspectum Diagnostics; Pfizer Inc.; Sanofi-Aventis; SomaLogic, Inc.; Takeda Pharmaceuticals North America, Inc.; Tobira Therapeutics; Vertex Pharmaceuticals Incorporated
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Intercept; Inventiva
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Allergan, Inc.; Conatus Pharmaceuticals Inc.; Corcept Therapeutics Inc.; Enanta Pharmaceuticals, Inc.; Gilead Sciences, Inc.
Served as a speaker or a member of a speakers bureau for: Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.
Received grants for clinical research from: Allergan, Inc.; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Prometheus Laboratories Inc.; Zydus Pharmaceuticals, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: 3-V Biosciences, Inc.; Allergan, Inc.; Bristol-Myers Squibb Company; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Fractyl Laboratories, Inc.; Gelesis; GENFIT SA; Gilead Sciences, Inc.; Immuron; Intercept Pharmaceuticals, Inc.; Madrigal Pharmaceuticals, Inc.; Merck & Co., Inc.; Metacrine; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Thetis Pharmaceuticals LLC; Viking Therapeutics
Received grants for clinical research from: Novartis Pharmaceuticals Corporation
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: 3-V Biosciences, Inc.; AbbVie Inc.; Allergan, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Echosens; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Novo Nordisk; Perspectum Diagnostics; Pfizer Inc.; TARGET PharmaSolutions, Inc.; Terns Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Echosens; Gilead Sciences, Inc.; Merck & Co., Inc.
Received grants for clinical research from: Gilead Sciences, Inc.